Sitemap
Posts
- Category: General (continued)
- Interview With RedHill Biopharma CEO Sheds Light On Pricing, Strategy and Near-Term Catalysts
- Is Relmada's d-Methadone The Next Big Thing?
- JPM Meeting Notes - Actinium Pharmaceuticals (ATNM)
- JPM Meeting Notes - BriaCell Therapeutics (BCT.V)
- JPM Meeting Notes - MabVax Therapeutics (MBVX)
- JPM Meeting Notes - Matinas Biopharma (MTNB)
- JPM Meeting Notes - RedHill Biopharma (RDHL)
- JPM Meeting Notes - VistaGen Therapeutics (VTGN)
- MabVax Looks Very Interesting Ahead Of Data Later This Month
- MabVax Phase 1 Trial With HuMab-5B1 Progressing Nicely
- Narcotic Bowel Syndrome An Intriguing Opportunity For Vitality Biopharma
- NMDA Receptor Targeting Offers New Hope For Severely Depressed
- Oasmia Leveraging Platform, Advancing Veterinary Medicines
- Oasmia Looks To Duplicate Success With A Validated Model
- Oasmia Pharmaceuticals – Advancing Nanotechnology Based Chemotherapies
- Phase 2 Data With RHB-104 In Multiple Sclerosis Expected Soon
- Phase 2 Mesupron Expands RedHill's Efforts In Oncology
- Putting A Value On BioSig's PURE EP
- RedHill Biopharma Packed With Catalysts In 2016
- RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
- RedHill's Phase 3 Crohn's Drug Is A Potential A Game-Changer
- RedHill's Pipeline Offers Significant Value For Investors
- RHB-105: The Medical Market Perspective (Part 1)
- SRNT Abstracts on SPECTRUM® Cigarettes Show Potential Market Opportunity For 22nd Century Group
- Time To Go Long Brainstorm Cell Therapeutics?
- Update On BriaCell Therapeutics Following Meeting With CEO
- Valeritas V-Go Saves Money, Improves Quality of Life
- Valeritas V-Go Targets An Enormous Market
- Vaxil Bio's ImMucin is a Novel Neoantigen With Significant Anticancer Potential
- VistaGen Licenses Regenerative Medicine Technology To BlueRock Therapeutics
- Vitality Biopharma Taking Cannabinoid Research To The Next Level
- What Does SGEN's Clinical Hold On CD33A Mean For Actinium?
- What's Next For BrainStorm Cell Therapeutics
- Why Immune Pharma Is So Excited About Bertilimumab In Ulcerative Colitis
- Why You Should Get To Know 22nd Century Group
- With One Successful Phase 3 Already Completed, RedHill Biopharma's RHB-105 Looks Like The New Standard For H. pylori Infection
- Category: Health and Wellness
- Category: Immune Pharma
- Category: Oryzon Genomics
- Category: Osiris Therapeutics